Wandercraft's AI-Powered Exoskeleton in Clinical Trials to Help Individuals with Mobility Issues

Wandercraft, a robotics startup, is developing an AI-powered exoskeleton that enables users with spinal cord injuries or neuromuscular disorders to stand and walk with stability and movement control. The Personal Exoskeleton is currently in clinical trials and uses NVIDIA technologies to accelerate workflows and bring new capabilities to the device. The team aims to enable users to walk at an average pace and perform everyday activities with ease.

Title: The Growing Potential of AI-Powered Exoskeletons in the Rehabilitation Robots Market

The rehabilitation robots market is poised for significant growth, driven by advancements in artificial intelligence and increased demand for robotic-assisted rehabilitation. According to a recent report by SNS Insider [1], the market is projected to reach USD 1,335.52 million by 2032, registering a CAGR of 18.76% from 2024 to 2032. This growth is largely attributed to the rising incidence of disabilities and neurological conditions, as well as the adoption of AI-based robotic systems.

Wandercraft, a robotics startup, is at the forefront of this trend with its AI-powered exoskeleton. The Personal Exoskeleton is currently in clinical trials and aims to enable users with spinal cord injuries or neuromuscular disorders to stand and walk with stability and movement control. Utilizing NVIDIA technologies, the exoskeleton aims to accelerate workflows and bring new capabilities to the device, enabling users to walk at an average pace and perform everyday activities with ease.

The U.S. market for rehabilitation robots is particularly robust, with strong momentum driven by veterans' healthcare establishments, private rehab centers, and an aging population. According to SNS Insider [1], the U.S. market was valued at USD 93.18 million in 2023 and is estimated to reach USD 459.2 million by 2032, growing at a CAGR of 18.97%.

Lifeward (LFWD) has also made significant strides in this market. In April 2023, the company received insurance approval for the ReWalk 7 Personal Exoskeleton, marking a pioneering step in broadening access to exoskeleton technology [2]. This development aligns with the broader trend of increased reimbursement for robotic rehabilitation services, which is expected to further boost market growth.

Key players in the rehabilitation robots market include Hocoma AG, Ekso Bionics Holdings, Inc., ReWalk Robotics, and Cyberdyne Inc., among others. These companies are expanding their product portfolios and sales channels to capture a larger share of the market.

The market's growth is also supported by technological advancements and increased healthcare infrastructure. AI-based robotic systems are making rehabilitation processes more efficient, while an increase in healthcare infrastructure is making these technologies more accessible.

In conclusion, the rehabilitation robots market is experiencing rapid growth, driven by advancements in AI and increased demand for robotic-assisted rehabilitation. Wandercraft's AI-powered exoskeleton and Lifeward's ReWalk 7 are notable examples of the innovative technologies entering this market. As the market continues to grow, investors and financial professionals should keep an eye on these developments and the broader trends shaping the rehabilitation robots landscape.

References

[1] https://www.globenewswire.com/news-release/2025/04/25/3068282/0/en/Rehabilitation-Robots-Market-to-Hit-USD-1-33-Billion-by-2032-Growing-at-18-76-CAGR-SNS-Insider-Report.html
[2] https://www.gurufocus.com/news/2811847/lifeward-lfwd-secures-insurance-approval-for-rewalk-7-exoskeleton-lfwd-stock-news